Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $25.21 --0%
EPS Growth %: -12.8%
Financial Fact:
Income from continuing operations: 1.32B
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -12.8%
Financial Fact:
Income from continuing operations: 1.32B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q3 EPS of $0.87, $0.21 better than the analyst estimate of $0.66. Revenue for the quarter came in at $16.7 billion versus the consensus estimate of $16.8 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $3.00-$3.15, versus the consensus of $3.04. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $62.8 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer reaffirms 2026 guidance after CFO transition news
- Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
- NIQ expands GeoPurchase audiences to four new countries
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
